Monte Rosa Therapeutics, Inc. (GLUE) key performance indicators and operating metrics (2 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Collaboration Revenue | 4.2M | FY2026-Q1 |
| Disease Control Rate in Solid Tumors (Response Evaluation Criteria in Solid Tumors) | 67.00 percent | FY2026-Q1 |
Back to GLUE overview · GLUE earnings · GLUE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.